Rothwell Investment Advisors, LLC’s Novavax NVAX Stock Holding History

Rothwell Investment Advisors, LLC’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$584	Buy	+54	New	+$484	﹤0.01%	1090

Other funds holding NVAX

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

Rothwell Investment Advisors, LLC's NVAX Position: Q3 2026 in Review

Rothwell Investment Advisors, LLC opened a new position in Novavax (NVAX) in Q3 2026: 54 shares worth $584. The stake represents ﹤0.01% of the portfolio and ranks #1090 among its holdings.

97 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

Rothwell Investment Advisors, LLC held 54 shares of Novavax worth $584 as of Q3 2026.
Novavax was a new Rothwell Investment Advisors, LLC position in Q3 2026.
Novavax made up ﹤0.01% of Rothwell Investment Advisors, LLC's portfolio in Q3 2026, its #1090 holding.
97 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on Rothwell Investment Advisors, LLC's 13F filing for Q3 2026, filed 6 Nov 2026.